| 摘要: |
| 目的:评价低剂量利妥昔单抗(RTX)用于儿童激素依赖型肾病综合征(SDNS)或频繁复发型肾病综合征(FRNS)的有效 性和安全性。 方法:收集我院肾脏免疫科 2020 年 1 月至 2022 年 7 月应用 RTX 治疗的 SDNS 和 FRNS 患儿临床资料,包括患儿 性别、年龄、持续缓解时间、RTX 使用前 1 年与治疗 1 年后的复发次数以及糖皮质激素、他克莫司的使用剂量,并将 RTX 治疗前 后相关指标进行统计分析。 结果:共收集 31 例 SDNS / FRNS 患儿,起病年龄为 5. 0(3. 2,9. 5)岁,初始使用 RTX 的年龄为(10. 0± 0. 7)岁,随访时间为 1. 1(1. 0,1. 5)年。 与使用 RTX 治疗前相比,RTX 治疗 1 年后复发次数、糖皮质激素以及他克莫司的使用剂 量均降低(P<0. 01)。 超敏反应是最常见的不良反应,无因感染导致死亡的病例发生。 结论:对于 SDNS / FRNS 患儿,低剂量 RTX 治疗方案展现出良好的有效性及安全性。 |
| 关键词: 利妥昔单抗 激素依赖型肾病综合征 频繁复发型肾病综合征 有效性 安全性 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2025.09.011 |
|
| 基金项目:江苏省药学会-天晴医院药学基金,编号 Q202120。 |
|
| Efficacy and Safety of Low-Dose Rituximab in the Treatment of Children with Nephrotic Syndrome |
| Yao Hua, Zhu Zengyan, Li Guifeng, Wang Fengjiao |
| (Children’ s Hospital of Soochow University, Jiangsu Suzhou 215000, China) |
| Abstract: |
| Objective: To evaluate the efficacy and safety of low-dose rituximab (RTX) in children with steroid-dependent nephrotic syndrome (SDNS) or frequent recurrent nephrotic syndrome (FRNS). Methods: Clinical data of SDNS / FRNS children treated with RTX from Jan. 2020 to Jul. 2022 in the Department of Nephrology and Immunology at Children’s Hospital of Soochow University were retrospectively analyzed, including gender, age, duration of sustained remission, annual recurrence frequency before and after RTX treatment, and dosage adjustment of glucocorticoids and tacrolimus. Relevant indicators before and after RTX treatment were statistically analyzed. Results: A total of 31 SDNS / FRNS children were enrolled, with disease onset at 5. 0 (3. 2, 9. 5) years and initial RTX administration age of (10. 0± 0. 73) years. The median follow-up duration was 1. 1 ( 1. 0, 1. 5) years. Compared with before RTX treatment, annual recurrence frequency and dosage of glucocorticoids and tacrolimus decreased after RTX treatment ( P < 0. 01). Hypersensitivity reactions were the most common adverse drug reactions, with no infection-related fatalities reported. Conclusion: Low-dose RTX demonstrates favorable therapeutic efficacy and safety profiles in children with SDNS / FRNS. |
| Key words: rituximab steroid-dependent nephrotic syndrome frequent recurrent nephrotic syndrome efficacy safety |
